Connect your AI

Mannkind MNKD In Process Research And Development Ready Flow Auto Formulation

In Process Research And Development Ready Flow Auto Formulation at other companies

SavaraSVRA

$11.36M+5.9%

NuScale PowerSMR

$16.9M0.0%

Crane NXT, Inc.CXT

$45.5M0.0%

Opko HealthOPK

$195M0.0%

Harmony Biosciences Holdings, Inc.HRMY

$32M—

Rumble, Inc.RUM

$716.55K—

Other financials

Income statement

Revenue$90.2M+15.1%

Gross profit$82.7M+10.8%

Operating income-$1.7M-107%

Net income-$16.6M-226%

EPS (diluted)-$0.05-225%

Balance sheet

Cash & equivalents$52.8M+11.7%

Total debt$12.2M-9.4%

Total equity-$59.2M-1.0%

Total assets$744.4M+81.5%

Cash flow

Operating cash flow-$5.4M+15.9%

CapEx$1.9M+470%

Free cash flow-$7.2M-8.0%

Valuation

Market cap$1.19B+3.5%

Enterprise value$1.15B+3.0%

P/E228.5×—

P/S3.3×-0.6×

Profitability

Gross margin91.5%-2.6pp

Operating margin23.3%+3.1pp

Net margin9.3%—

FCF margin13.8%—

Returns & leverage

Return on equity-8.8%—

Debt / equity-0.2×—

Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:InProcessResearchAndDevelopmentReadyFlowAutoFormulation.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's in process research and development ready flow auto formulation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Mannkind's in process research and development ready flow auto formulation?: Mannkind (MNKD) reported in process research and development ready flow auto formulation of $129.6M in Q1 2026.
What does in process research and development ready flow auto formulation mean?: This represents the fair value of acquired or internally developed research and development projects that have not yet reached technological feasibility. It captures the potential future value of pipeline assets, such as automated formulation technologies, that are currently in the development phase. These assets are not amortized but are evaluated periodically for impairment.